Centessa is advancing ORX750 to pivotal trials based on the Phase IIa data. Image credit: SOPA Images /LightRocket via Getty Images Centessa Pharmaceuticals executives will be breathing a sigh of ...
Novo Nordisk said that the data suggests that the benefits of Wegovy go further than just weight loss in the patient population. Image credit: PJ McDonnell / Shutterstock.com. Novo Nordisk’s oral ...
Despite the trial failure, Sarepta will still seek full approval of AMONDYS 45 and VYONDYS 53 in DMD from the FDA.
At the European Society for Medical Oncology (ESMO) 2025 event, held in Berlin, Germany, between 17-21 October, Celcuity ...
While AstraZeneca's gefurulimab offered significant improvements to MG-ADL scores, it was bested by a variety of ...
Accurately tracking trial initiations has often been a challenge because start dates are not always disclosed or are reported incorrectly. Credit: Ihar Halavach via Shutterstock.com. According to ...
The company’s stock rose significantly after it announced the full Phase I/II data. Image credit: Lightspring / Shutterstock.com. Intensity Therapeutics’ stock has risen nearly 400% after its oncology ...
In a Phase I trial, biomarkers seem to suggest the potential for a once or twice yearly dosing of Wave’s siRNA for weight ...
AbbVie's Rinvoq will have to come up against Pfizer’s prospective and Incyte’s approved JAK inhibitors in the non-segmental ...
The app helps sites and patients stay synchronised, supporting compliance. Credit: SOMKID THONGDEE/Shutterstock.com. US-based software company Suvoda has launched a unified patient mobile app to ease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback